课题基金 / 基金详情

Investigating L-2-hydroxyglutarate in normal hematopoiesis and leukemogenesis

Investigating L-2-hydroxyglutarate in normal hematopoiesis and leukemogenesis
研究 L-2-羟基戊二酸在正常造血和白血病发生中的作用
批准号:
9762582
负责人:
Andrew Michael Intlekofer
金额:
$17.73万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-09-14 至 2021-08-31
关键词:
Acute Myelocytic LeukemiaAffectBiochemicalBiologicalBiological AssayBone MarrowCell Culture SystemCell Differentiation processCellsCellular Metabolic ProcessCharacteristicsChromatinChromatin StructureClinicalCytosineDNADataEmbryoEnvironmentEnzymesEpigenetic ProcessExhibitsFundingGene ExpressionGoalsHematologyHematopoiesisHematopoieticHematopoietic stem cellsHistonesHumanHypoxiaHypoxia Inducible FactorIn VitroInternationalInvestigationIsocitrate DehydrogenaseLaboratoriesLactate DehydrogenaseLeukemic CellLymphomaMalignant - descriptorMalignant NeoplasmsMediatingMemorial Sloan-Kettering Cancer CenterMentorsMentorshipMetabolicMetabolic PathwayMetabolismMethylationModificationMolecularMolecular AbnormalityMusMutationNormal CellOxygenPathogenesisPathway interactionsPatient-Focused OutcomesPatientsPharmaceutical PreparationsPhysiciansPhysiologicalPositioning AttributeProductionResearchResearch PersonnelRoleSamplingScientistServicesSomatic MutationSourceStem cellsStereoisomerStructural GenesSystemTestingTherapeuticTherapeutic InterventionTrainingUndifferentiatedalpha ketoglutaratecancer cellcancer therapycareerchiral moleculechromatin modificationcohortdelta opioid receptorenantiomerexperiencehematopoietic differentiationhistone modificationimproved outcomein vivoinhibitor/antagonistleukemialeukemic transformationleukemogenesismouse modelmutantnew therapeutic targetnovel therapeuticsoncologypatient subsetsprogramsresponseself-renewalsmall molecule inhibitorstemstem cell populationtargeted treatmenttherapeutic targettumor metabolism

项目摘要

项目成果

Andrew Michael Intlekofer的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要/摘要 异柠檬酸脱氢酶(IDH)酶的体细胞突变在急性 髓系白血病(AML)和其他恶性肿瘤通过产生‘肿瘤性代谢物’D-2-羟基戊二酸 (d-2HG)。D-2HG通过抑制α-酮戊二酸(α-KG)依赖性阻断肿瘤细胞的分化 调节染色质结构和基因表达的酶。突变型IDH的小分子抑制剂 酶类正在成为治疗急性髓细胞白血病患者的有希望的新疗法,但其疗效仍局限于 IDH突变患者的亚群。2HG是一种手性分子,可以存在于D-或L-中- 对映体。生化分析表明,L-2HG比D-2HG具有更强的抑制血管紧张素转换酶的作用 αKG依赖的染色质修饰酶,但L-2HG的生物来源和活性较差 明白了。这项提案中提供的初步数据描述了一种以前未知的代谢途径 在氧气限制条件下(也称为低氧)时,细胞可通过 乳酸脱氢酶对αKG的杂合酶促还原。L-2HG稳定低氧诱导因子 1α(HIF1α),并增加未分化/干细胞状态的抑制性组蛋白修饰。 低氧诱导的L-2HG通路在原代胚胎干细胞和造血干细胞中是活跃的 (ESCs/HSCs)和白血病细胞,以及增加L-2HG水平的实验操作阻断 原代HSCs和ESCs的分化。正常的血液干细胞和白血病细胞存在并依赖于 在骨髓的缺氧区。因此,L-2HG可能代表了一种分子机制 低氧生态位促进和维持正常血液干细胞和白血病的未成熟状态 干细胞/祖细胞。这一假说将通过(1)使用体外系统来阐明 L-2HG对造血细胞基因表达、表观遗传修饰和分化的影响(2) 利用体内小鼠模型确定L-2HG对正常或恶性造血的影响,以及(3) 利用患者样本确定L-2HG代谢失调是否为人类白血病的一个特征。这个 拟议的研究将扩大针对癌症2HG的治疗策略, 尤其是对于大量缺乏IDH突变的患者。申请人Andrew Intlekofer博士是 纪念斯隆·凯特琳癌症中心(MSKCC)淋巴瘤服务的助理主治医生 概述了他在研究细胞分子机制方面的研究背景的5年职业计划 肿瘤学和恶性血液学的辨证和临床训练。Intlekofer博士将主持 在克雷格·汤普森博士的指导下拟议的研究,他是一位国际公认的 具有培养成功内科科学家的良好记录的癌症新陈代谢专家。MSKCC提供 为Intlekofer博士启动拟议的研究计划和过渡到 拥有自己的实验室和R01资金的独立学术研究员的职位。
英文摘要
PROJECT SUMMARY/ABSTRACT Somatic mutations in the isocitrate dehydrogenase (IDH) enzymes contribute to the pathogenesis of acute myeloid leukemia (AML) and other malignancies via production of the `oncometabolite' D-2-hydroxyglutarate (D-2HG). D-2HG blocks differentiation of malignant cells by inhibiting α-ketoglutarate (αKG)-dependent enzymes that regulate chromatin structure and gene expression. Small molecule inhibitors of mutant IDH enzymes are emerging as promising new therapies for patients with AML, but their efficacy remains limited to the subset of patients with IDH mutations. 2HG is a chiral molecule that can exist in either the D- or L- enantiomer. Biochemical assays show that L-2HG functions much more potently than D-2HG as an inhibitor of αKG-dependent chromatin-modifying enzymes, but biological sources and activities of L-2HG are poorly understood. Preliminary data presented in this proposal describe a previously unknown metabolic pathway where under conditions of oxygen limitation (a.k.a. hypoxia), cells potently and selectively produce L-2HG via promiscuous enzymatic reduction of αKG by lactate dehydrogenase. L-2HG stabilizes hypoxia-inducible factor 1α (HIF1α) and increases repressive histone modifications characteristic of the undifferentiated/stem cell state. The hypoxia-induced L-2HG pathway is active in primary embryonic and hematopoietic stem cells (ESCs/HSCs) and leukemia cells, and experimental manipulations that increase L-2HG levels block the differentiation of primary HSCs and ESCs. Normal blood stem cells and leukemia cells reside in and depend on hypoxic regions of the bone marrow. Thus, L-2HG might represent a molecular mechanism whereby hypoxic niches promote and maintain the immature state of normal blood stem cells and leukemia stem/progenitor cells. This hypothesis will be rigorously tested by (1) using in vitro systems to elucidate the effects of L-2HG on hematopoietic cell gene expression, epigenetic modifications, and differentiation, (2) employing in vivo mouse models to determine if L-2HG influences normal or malignant hematopoiesis, and (3) utilizing patient samples to determine if deregulated L-2HG metabolism is a feature of human leukemia. The proposed investigations will expand the armamentarium of strategies to therapeutically target 2HG in cancer, particularly for the large cohort of patients who lack IDH mutations. The applicant, Dr. Andrew Intlekofer, an Assistant Attending with the Lymphoma Service at Memorial Sloan Kettering Cancer Center (MSKCC), has outlined a 5-year career plan that builds upon his research background studying molecular mechanisms of cell differentiation and his clinical training in oncology and malignant hematology. Dr. Intlekofer will conduct the proposed research under the mentorship of Dr. Craig Thompson, an internationally recognized expert in cancer metabolism with a strong track record of training successful physician scientists. MSKCC provides the ideal institutional environment for Dr. Intlekofer to embark on the proposed research program and transition to a position as an independent academic investigator with his own laboratory and R01 funding.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Metabolic control of normal and malignant hematopoiesis
  • 批准号:
    10642846
  • 项目类别:
  • 资助金额:
    $47.51万
  • 财政年份:
    2020
  • 负责人:
    Andrew Michael Intlekofer
  • 依托单位:
Metabolic control of normal and malignant hematopoiesis
  • 批准号:
    10033070
  • 项目类别:
  • 资助金额:
    $48.48万
  • 财政年份:
    2020
  • 负责人:
    Andrew Michael Intlekofer
  • 依托单位:
Metabolic control of normal and malignant hematopoiesis
  • 批准号:
    10408832
  • 项目类别:
  • 资助金额:
    $48.48万
  • 财政年份:
    2020
  • 负责人:
    Andrew Michael Intlekofer
  • 依托单位:
Metabolic control of normal and malignant hematopoiesis
  • 批准号:
    10246455
  • 项目类别:
  • 资助金额:
    $48.48万
  • 财政年份:
    2020
  • 负责人:
    Andrew Michael Intlekofer
  • 依托单位:
海外基金